News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Rituximab with BEAM Conditioning Prior to Auto-HCT for DLBCL not Recommended

Feb 27, 2020
Hannah Slater

This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.

In a large registry analysis of patients with diffuse large B-cell lymphoma (DLBCL) undergoing auto-HCT, published in Cancer, the addition of rituximab (Rituxan) to the BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen had no impact on transplantation outcomes. 

Additionally, older age, absence of complete response (CR) pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival. Given these findings, routine use of rituximab with BEAM conditioning prior to auto-HCT for DLBCL is not recommended.

“In the modern era, where rituximab is an integral part of DLBCL therapy, both in the up-front and relapsed setting, additional rituximab exposure with the conditioning chemotherapy does not appear to impact transplantation outcomes,” the authors wrote. 

Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, researchers assessed 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM conditioning regimen. The cohort was divided into 2 groups, with 667 patients only using the BEAM conditioning regimen and the remaining 195 receiving rituximab in addition to BEAM (R-BEAM).

On multivariate analysis, no significant difference was observed in overall survival (OS; P = 0.83) or progression-free survival (PFS; P = 0.61) across the 2 cohorts. The 4-year OS was 61% (95% CI, 57%-65%) in the BEAM cohort compared to 58% (95% CI, 51%-65%) in the R-BEAM group (P = 0.77). Moreover, the 4-year PFS in the BEAM group was 47% (95% CI, 43%-51%) compared to 48% (95% CI, 41%-56%) in the R-BEAM group.

No significant association between the use of rituximab and risk of relapse (P = 0.15) or non-relapse mortality (P = 0.12) was seen. Institutional practice varies in regard to rituximab dose intensity and administration schedule in auto-HCT conditioning according to the researchers. Though it is plausible that higher rituximab doses intensity may improve auto-HCT outcomes, patients who received a higher dose of rituximab (>375 mg/m2) in this study had a similar relapse rate and survival compared with patients receiving the standard 375 mg/m2 dose. 

“In the contemporary era, the benefit of combining an anti-CD20 monoclonal antibody with auto-HCT conditioning regiments is yet to be determined,” the authors wrote. “Prospective data incorporating rituximab with conditioning regimens are from nonrandomized studies or lack a BEAM-only comparative arm.”

Variables that were independently associated with lower OS included older age at auto-HCT (P < 0.001), absence of CR at auto-HCT (P < 0.001) and early chemoimmunotherapy failure (P < 0.001). Older age (P < 0.0002) and non-CR pre-HCT (P < 0.0001) were also associated with inferior PFS. Notably, progressive disease was the major cause of death in 68% and 55% of patients in the BEAM and R-BEAM cohorts, respectively. Infection was found to be a contributing secondary cause of death in 5% of BEAM deaths and 6% of R-BEAM deaths. 

Previously conducted multicenter and single institution retrospective studies have validated early rituximab-based regimen failure as a negative predictor for transplantation outcomes. Moreover, researchers indicated that post-transplantation maintenance is another attractive treatment modality in the ongoing efforts to reduce post-HCT relapse. 

“Due to lack of evidence, the (American Society for Blood and Marrow Transplantation), CIBMTR, and (European Society for Blood and Marrow Transplantation) joint consensus statement does not endorse post auto-HCT maintenance treatment in patients with DLBCL,” the authors wrote. “Results from the ongoing BMT CTN phase III randomized trial will address whether maintenance ibrutinib (Imbruvica) after auto-HCT can impact outcomes in nongerminal center DLBCL (NCT02443077).” 

Reference:

Jagadeesh D, Majhail NS, He Y, et al. Outcomes of Rituximab-BEAM Versus BEAM Conditioning Regimen in Patients With Diffuse Large B Cell Lymphoma Undergoing Autologous Transplantation. Cancer. doi:10.1002/cncr.32752.

Related Videos
Andre H. Goy, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on diffuse large B-cell lymphoma
Andre Goy, MD, an expert on mantle cell lymphoma
André Goy, MD, an expert on B-cell malignancies
André Goy, MD, an expert on B-cell malignancies
André Goy, MD, an expert on B-cell malignancies
André Goy, MD, an expert on B-cell malignancies
Related Content

Old Age ‘Should Not Prohibit’ Cellular Therapy Use in Large B-Cell Lymphoma

May 27th 2023

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

August 23rd 2022

FDA Clears IND for AFM13/AB-101 in R/R Classical Hodgkin Lymphoma

May 23rd 2023

Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

August 30th 2021

FDA Approves Epcoritamab for Relapsed/Refractory DLBCL and High-Grade B-Cell Lymphoma

May 19th 2023

FDA Gives Novel CAR T Therapy FTD in R/R Aggressive B-Cell Lymphoma

May 16th 2023

Old Age ‘Should Not Prohibit’ Cellular Therapy Use in Large B-Cell Lymphoma

May 27th 2023

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

August 23rd 2022

FDA Clears IND for AFM13/AB-101 in R/R Classical Hodgkin Lymphoma

May 23rd 2023

Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

August 30th 2021

FDA Approves Epcoritamab for Relapsed/Refractory DLBCL and High-Grade B-Cell Lymphoma

May 19th 2023

FDA Gives Novel CAR T Therapy FTD in R/R Aggressive B-Cell Lymphoma

May 16th 2023

Old Age ‘Should Not Prohibit’ Cellular Therapy Use in Large B-Cell Lymphoma

May 27th 2023

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

August 23rd 2022

FDA Clears IND for AFM13/AB-101 in R/R Classical Hodgkin Lymphoma

May 23rd 2023

Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

August 30th 2021

FDA Approves Epcoritamab for Relapsed/Refractory DLBCL and High-Grade B-Cell Lymphoma

May 19th 2023

FDA Gives Novel CAR T Therapy FTD in R/R Aggressive B-Cell Lymphoma

May 16th 2023
Related Content

Axicabtagene ciloleucel may prolong survival and improve outcomes vs standard-of-care therapy in older patients with relapsed/refractory large B-cell lymphoma.

Old Age ‘Should Not Prohibit’ Cellular Therapy Use in Large B-Cell Lymphoma

May 27th 2023
Article

Axicabtagene ciloleucel may prolong survival and improve outcomes vs standard-of-care therapy in older patients with relapsed/refractory large B-cell lymphoma.


Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell Lymphoma

August 23rd 2022
Podcast

Robert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.


Investigators plan to initiate a phase 2 study evaluating AFM13 plus AB-101 in patients with relapsed/refractory classical Hodgkin lymphoma in the first half of 2024.

FDA Clears IND for AFM13/AB-101 in R/R Classical Hodgkin Lymphoma

May 23rd 2023
Article

Investigators plan to initiate a phase 2 study evaluating AFM13 plus AB-101 in patients with relapsed/refractory classical Hodgkin lymphoma in the first half of 2024.


Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.

Oncology Peer Review On-The-Go: Two Experts Review Important R/R DLBCL Treatment Decisions and Data

August 30th 2021
Podcast

Gilles Salles, MD, PhD, and Kami Maddocks, MD, discuss relapsed/refractory diffuse large B-cell lymphoma therapeutic options and important data from the L-MIND trial.


Patients with relapsed/refractory diffuse large B-cell lymphoma can now receive epcoritamab following the FDA’s approval of the agent.

FDA Approves Epcoritamab for Relapsed/Refractory DLBCL and High-Grade B-Cell Lymphoma

May 19th 2023
Article

Patients with relapsed/refractory diffuse large B-cell lymphoma can now receive epcoritamab following the FDA’s approval of the agent.


Investigators are expected to share initial safety and efficacy data from a phase 1/2 trial assessing IMPT-314 as a treatment for aggressive B-cell lymphoma in the second half of 2023.

FDA Gives Novel CAR T Therapy FTD in R/R Aggressive B-Cell Lymphoma

May 16th 2023
Article

Investigators are expected to share initial safety and efficacy data from a phase 1/2 trial assessing IMPT-314 as a treatment for aggressive B-cell lymphoma in the second half of 2023.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.